Search
Savara Inc
SVRAAdd to Watchlist
5.050USD
+0.050+1.00%
Market hours 09/24, 14:34（ET）
1.03BMarket Cap
LossP/E TTM
About Savara Inc Company
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Savara Inc Profile
Ticker SymbolSVRA
Company nameSavara Inc
IPO dateJun 25, 2001
CEOPauls (Matthew)
Number of employees59
Security typeOrdinary Share
Fiscal year-endJun 25
Address6836 Bee Cave Road
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78746
Phone151285113796
Websitehttps://savarapharma.com/
Ticker SymbolSVRA
IPO dateJun 25, 2001
CEOPauls (Matthew)
Company Executives of Savara Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Dr. Joseph S. (Joe) McCracken, Ph.D.
Dr. Joseph S. (Joe) McCracken, Ph.D.
Lead Independent Director
Lead Independent Director
260.84K
-0.69%
Dr. Joseph S. (Joe) McCracken, Ph.D.
Dr. Joseph S. (Joe) McCracken, Ph.D.
Lead Independent Director
Lead Independent Director
260.84K
-0.69%
Dr. Joseph S. (Joe) McCracken, Ph.D.
Dr. Joseph S. (Joe) McCracken, Ph.D.
Lead Independent Director
Lead Independent Director
260.84K
-0.69%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Financial and Chief Operating Officer
Chief Financial and Chief Operating Officer
228.98K
+15.29%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Financial and Chief Operating Officer
Chief Financial and Chief Operating Officer
228.98K
+15.29%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Financial and Chief Operating Officer
Chief Financial and Chief Operating Officer
228.98K
+15.29%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business & Corporate Affairs Officer
Chief Business & Corporate Affairs Officer
132.03K
-47.69%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Dr. Joseph S. (Joe) McCracken, Ph.D.
Dr. Joseph S. (Joe) McCracken, Ph.D.
Lead Independent Director
Lead Independent Director
260.84K
-0.69%
Dr. Joseph S. (Joe) McCracken, Ph.D.
Dr. Joseph S. (Joe) McCracken, Ph.D.
Lead Independent Director
Lead Independent Director
260.84K
-0.69%
Dr. Joseph S. (Joe) McCracken, Ph.D.
Dr. Joseph S. (Joe) McCracken, Ph.D.
Lead Independent Director
Lead Independent Director
260.84K
-0.69%
FAQs
Who are the top five shareholders of Savara Inc?
The top five shareholders of Savara Inc are: Mr. David A. Ramsay
How many institutions hold shares of Savara Inc (SVRA)?
As of 2026Q1, 324 institutions hold shares of Savara Inc, with a combined market value of approximately 213.87M, accounting for 104.36% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 19143564.00.